Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Net Income towards Common Stockholders rose 12846.91% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 14415.3%. This contributed to the annual value of -$64.0 million for FY2024, which is 1594.04% down from last year.
  • As of Q3 2025, Theravance Biopharma's Net Income towards Common Stockholders stood at $3.6 million, which was up 12846.91% from $54.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Net Income towards Common Stockholders registered a high of $927.1 million during Q3 2022, and its lowest value of -$23.1 million during Q4 2024.
  • In the last 5 years, Theravance Biopharma's Net Income towards Common Stockholders had a median value of $3.6 million in 2025 and averaged $50.3 million.
  • In the last 5 years, Theravance Biopharma's Net Income towards Common Stockholders skyrocketed by 440000.49% in 2022 and then crashed by 31854.13% in 2023.
  • Over the past 5 years, Theravance Biopharma's Net Income towards Common Stockholders (Quarter) stood at $25.8 million in 2021, then crashed by 84.9% to $3.9 million in 2022, then crashed by 318.54% to -$8.5 million in 2023, then tumbled by 171.45% to -$23.1 million in 2024, then skyrocketed by 115.65% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $54.8 million for Q2 2025, and -$13.5 million during Q1 2025.